Table 3.

Clinical history and treatment outcome of mTNBC

ParticipantTreatment while on sequencing studyBest-response disease siteAdditional history and best response
mTNBC1BEZ235 (PI3K/mTOR inhibitor)SDpCR: preoperative AC/T;
Chest wallPR: iniparib/gemcitibine/carboplatin;
PD: bortezomib/cyclophosphamide/peg­ylated liposomal doxorubicin
mTNBC2Trametinib (MEK inhibitor) + GSK2141795 (AKT inhibitor)PRPR: gemcitabine/carboplatin; docetaxel/cyclophosphamide; paclitaxel/bevacizumab
BreastPD: doxorubicin/cyclophosphamide
mTNBC3BEZ235 (PI3K/mTOR inhibitor)PDSD: iniparib/gemcitabine/carboplatin
Lung
mTNBC4EribulinSDPR: ixabepilone/capecitabine;
Lung/nodesPD: iniparib/gemcitabine/carboplatin;
PD: bortezomib/cyclophosphamide/pegylated liposomal doxorubicin
mTNBC5EZN 2208 (TOPO1 inhibitor)PRPR: preoperative AC/T;
NodesPD: iniparib/gemcitabine/carboplatin
mTNBC6Paclitaxel + bevacizumab + everolimus (mTOR inhibitor)CRNo response to preoperative AC/T
Chest wall
mTNBC7Trametinib (MEK inhibitor) + GSK2141795 (AKT inhibitor)PDChest wallPrimary refractory to all cytotoxic agents
CR: nab-paclitaxel/bevacizumab/radiation
mTNBC8Iniparib + gemcitabine + carboplatinResponseBone-only metastatic disease at presentation
Bone
mTNBC9Iniparib + gemcitabine + carboplatinCRPR: preoperative AC/T;
NodesPD: iniparib/gemcitabine/carboplatin
mTNBC10EZN 2208 (TOPO1 inhibitor)PRPR: preoperative AC/T;
Chest wallPD: iniparib/gemcitabine/carboplatin
mTNBC11Iniparib + gemcitabine + carboplatinPDPrimary refractory to preoperative AC/T;
Marrow/CNSPD: iniparib/gemcitabine/carboplatin
Rapid death marrow and brain metastasis
mTNBC12Nab paclitaxel + capecitabinePRBone and diffuse adenopathy at presentation
Nodes
mTNBC13Iniparib + gemcitabine + carboplatinPRLiverBRCA2 mutation; ovarian cancer (paclitaxel/carboplatin) and bilateral breast cancer;
PD: ixabepilone/capecitabine
mTNBC14BEZ235 (PI3K/mTOR inhibitor)SDRegional lymphadenopathy primary refractory to all cytotoxic agents/radiation
21% Reduction in nodes

Abbreviations: AC/T, doxorubicin, cyclophosphamide, paclitaxel; CR, complete response; pCR, pathologic complete response; PD, progressive disease; PR, partial response; SD, stable disease.